Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-10-07
Target enrollment:
Participant gender:
Summary
HS-10376 is an oral, highly selective, small molecular inhibitor of EGFR/HER2 Exon 20
insertion mutation. This study will evaluate the safety, tolerability, pharmacokinetics and
clinical activity of HS-10376 in Chinese advanced Non-Small Cell Lung Cancer (NSCLC)
patients.